» Articles » PMID: 9737872

Formation of Proteasome-PA700 Complexes Directly Correlates with Activation of Peptidase Activity

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1998 Sep 16
PMID 9737872
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The proteolytic activity of the eukaryotic 20S proteasome is stimulated by a multisubunit activator, PA700, which forms both 1:1 and 2:1 complexes with the proteasome. Formation of the complexes is enhanced by an additional protein assembly called modulator, which also stimulates the enzymatic activity of the proteasome only in the presence of PA700. Here we show that the binding of PA700 to the proteasome is cooperative, as is the activation of the proteasome's intrinsic peptidase activity. Modulator increases the extent of complex formation and peptidase activation, while preserving the cooperative kinetics. Furthermore, the increase in activity is not linear with the number of PA700 assemblies bound to the proteasome, but rather with the number of proteasome-PA700 complexes, regardless of the PA700:proteasome stoichiometry. Hence the stimulation of peptidase activity is fully (or almost fully) effected by the binding of a single PA700 to the 20S proteasome. The stimulation of peptidase by modulator is explained entirely by the increased number of proteasome-PA700 complexes formed in its presence, rather than by any substantial direct stimulation of catalysis. These observations are consistent with a model in which PA700, either alone or assisted by modulator, promotes conformational changes in the proteasome that activate the catalytic sites and/or facilitate access of peptide substrates to these sites.

Citing Articles

Covalent Inhibition of the 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies.

Serrano-Aparicio N, Ferrer S, Swiderek K Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631358 PMC: 9143130. DOI: 10.3390/ph15050531.


The YΦ motif defines the structure-activity relationships of human 20S proteasome activators.

Opoku-Nsiah K, H de la Pena A, Williams S, Chopra N, Sali A, Lander G Nat Commun. 2022; 13(1):1226.

PMID: 35264557 PMC: 8907193. DOI: 10.1038/s41467-022-28864-x.


Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.

Lee M, Bhattarai D, Yoo J, Miller Z, Park J, Lee S J Med Chem. 2019; 62(9):4444-4455.

PMID: 30964987 PMC: 7675178. DOI: 10.1021/acs.jmedchem.8b01943.


A Practical Review of Proteasome Pharmacology.

Thibaudeau T, Smith D Pharmacol Rev. 2019; 71(2):170-197.

PMID: 30867233 PMC: 6423620. DOI: 10.1124/pr.117.015370.


A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.

Thibaudeau T, Anderson R, Smith D Nat Commun. 2018; 9(1):1097.

PMID: 29545515 PMC: 5854577. DOI: 10.1038/s41467-018-03509-0.